Bioequivalent test items flock to specific ingredients.

Published: 2001-08-13 06:59:00

Updated: 2001-08-13 06:59:00

It was found that the drugs completed with its bio-equivalent test and to be booked on the Common Prescription List with priority had been concentrated on specific ingredients, which may trigger a severe competition in the market and restrict chances for pharmacists to substitute in their dispens...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK